[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100542541":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":18,"responsibleParty":34,"collaborators":7,"id":36,"slug":37,"hasResults":38,"nctId":39,"briefTitle":40,"officialTitle":41,"acronym":42,"eligibilityCriteria":43,"healthyVolunteers":38,"sex":44,"minAge":45,"maxAge":46,"enrollmentInfo":47,"targetDuration":7,"studyType":50,"phases":7,"briefSummary":51,"conditions":52,"keywords":7,"overallStatus":20,"whyStopped":7,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":63},{"fullName":5,"class":6},"European Institute of Oncology","OTHER",null,[9,14],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"Maria Cossu Rocca, MD","CONTACT","00390294372900","maria.cossurocca@ieo.it",{"name":15,"role":11,"phone":16,"phoneExt":7,"email":17},"francesca lombardi","00390257489425","francesca.lombardi@ieo.it",[19],{"facility":5,"status":20,"city":21,"state":21,"zip":22,"country":23,"countryCode":24,"cosmosGeoPoint":25,"geoPoint":30,"contacts":31},"RECRUITING","Milan","20141","Italy","IT",{"type":26,"coordinates":27},"Point",[28,29],9.18951,45.46427,{"lat":29,"lon":28},[32],{"name":33,"role":11,"phone":12,"phoneExt":7,"email":13},"maria Cossu Rocca, MD",{"type":35,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100542541","predicting-toxicity-in-elderly-patients-with-head-and-neck-cancer-100542541",false,"NCT06344208","Predicting Toxicity in Elderly Patients With Head and Neck Cancer","Predicting Toxicity in Elderly Patients With Head and Neck Cancer: Validating a Disease-oriented Toxicity Predictive Tool and Integrating it With Available Screening Tools for Better Outcomes","PREtoxEL","Inclusion Criteria:\n\n* Patients aged ≥ 70 years\n* Histological diagnosis of squamous cell or undifferentiated HNC in stage III-IV AJCC ed VIII (si-nonasal, nasopharynx, oral cavity, oropharynx, unknown primary with HPV pos, larynx and hy-popharynx) and candidated to curative non surgical treatment (radiotherapy alone, Chemora-diation with platinum salts; radiation+cetuximab)\n* Evaluable disease accordingly to RECIST criteria 1.1\n* Willing of sign a written informed consent\n* Adequate organ function\n\nExclusion Criteria:\n\nPatient with cancer in other sites than HN \\\u003C than 2 years except for prostate cancer cT1-2, Gleason 3+3, NIMBC, initial Non Melanoma Skin Cancer, in situ cervical cancer)\n\n* PS ECOG 3-4\n* Patients who received systemic treatments in the past for other primary tumors","ALL","70 Years","99 Years",{"count":48,"type":49},3,"ESTIMATED","OBSERVATIONAL","Predicting toxicity in elderly patients with head and neck cancer:\n\nvalidating a disease-oriented toxicity predictive tool and integrating it with avail-able screening tools for better outcomes.",[53],"Head and Neck Cancer","2026-03-23",{"date":56,"type":57},"2026-03-24","ACTUAL",{"date":59,"type":57},"2022-03-15",{"date":61,"type":49},"2026-12-31",{"name":5,"class":6},1]